Ray Blanco — “Biotech’s UNSTOPPABLE”
Record highs and 15% gains year-to-date…
According to The Wall Street Journal this morning, that’s the S&P Biotechnology Select Index’s stellar performance in a nutshell this year.
Simply put, mid- and small-sized biotechs are surging.
But that’s not the only proof positive chart showing how hot biotechs truly are.
Large-caps are also outperforming the major indexes big time.
To date, the SPDR S&P Biotech ETF (XBI) is trouncing both S&P 500 and Dow gains by double digits. Here’s the year-to-date chart of all three for comparison.
This performance makes biotech hands down one of the best sectors around right now.
And it means tons of amazing profit chances ahead.
Compared to trade war drama and Helsinki developments biotech stories may not seem as captivating.
But the cold hard cash it could put in your pocket is the most important story you need to hear.
Which is why you can’t ignore biotech’s run-up if you want to walk away a market winner in 2018.
Here’s what’s fueling the surge.
Biotech IPOs Offer Quality Over Quantity
Today’s Journal report notes: “Upstart companies are taking advantage of this market strength, and investors are rewarding them.”
And while the slew of biotech IPOs we saw in previous years is waning, the offerings we’ve seen so far in 2018 are of the highest quality.
According to Dealogic data, biotech IPOs have added $3.4 billion in combined value so far this year, as reported by The Journal.
But that’s not the only catalyst helping biotech stocks soar.
Large-Cap Biotechs Thrive Off M&As
Another factor fueling biotech’s run-up is the strong trend of mergers and acquisitions this year.
The Journal reports, “big drugmakers, desperate to boost growth rates, are willing to pay up for relatively scarce high-quality biotechs.”
Which means large-cap biotechs are shelling out top-dollar for smaller, upstart companies in order to gain the rights to the most advanced breakthroughs and therapies.
Which also means big paydays for those owning shares of these smaller buyout targets.
But there’s also another major tailwind at play.
Dozens of New FDA Trials Ahead
We have at least 63 new FDA trial dates scheduled to review drugs for approval over the coming months.
If any number of these drugs gets a thumbs up, they’re free to start marketing the drug… and share prices could soar in anticipation.
That could mean up to 63 new profit plays coming soon. In addition to any new merger or IPO opportunities already upon us.
The bottom line: Biotech stocks took some time off to consolidate in the beginning of the year.
But fast forward to July and the sector is once again marching towards record highs and offering up juicy new trading opportunities.
Now’s the perfect time to lock yourself into biotech’s unstoppable breakout.
For Technology Profits Daily,
Chief Technology Expert, Technology Profits Daily
Editor’s note: We’re two days away from Ray Blanco unveiling the “World’s Fastest Fortune.”
Ray’s research has uncovered one tiny company that could grow to $100 billion faster than any other company in history.
This Friday July 20, Ray reveals how you can get FREE SHARES of this tiny opportunity before anyone else.
Final details tomorrow. Stay tuned!